FDA | NIH: Regulatory Do’s and Don’ts: Tips from FDA - CBER Segment

  Рет қаралды 1,101

U.S. Food and Drug Administration

U.S. Food and Drug Administration

2 ай бұрын

This inaugural webinar was a collaborative effort between FDA and NIH’s Small Business Innovation Research (SBIR) Development Center within the National Cancer Institute (NCI). Its purpose was to educate early-stage companies (small businesses) new to the regulatory landscape at the FDA. The genesis of this webinar can be attributed to the work that FDA, specifically SBIA, has contributed to NIH | SBIR in the past few years, and more recently with its Connecting Awardees with Regulatory Experts (CARE) Program.
Timestamps
01:42 - Overview of CBER’s Manufacturers Assistance and Technical Training Branch (MATT)
06:40 - Regulatory Resources and Avenues for Obtaining Early Guidance from CBER/OTP
17:24 - CBER’s CMC Considerations for Early Phase Studies of Cell and Gene Therapy Products
27:35 - Nonclinical Assessment of Cell and Gene Therapy Products to Support an IND
36:35 - Clinical Consideration for Cell and Gene Therapy in Early Phase Study
47:40 - Session II Q&A Panel
Speakers:
Loni Warren Henderson
Public Affairs Specialist
Manufacturers Assistance and Technical Training Branch
Division of Manufacturers Assistance and Training
Office of Communication Outreach and Development | CBER
Heather Erdman, MCPM, RAC, CQPA
Associate Director of Quality Assurance
Office of Review Management and Regulatory Review (ORMRR)
Office of Therapeutic Products (OTP) | CBER
Karin Knudson, PhD
CMC Reviewer
Office of Cellular Therapy and Human Tissue CMC (OCTHT)
OTP | CBER
Devaveena Dey, PhD
Pharmacology-Toxicology Reviewer
Office of Pharmacology-Toxicology (OPT) | OTP | CBER
Jessica Lee, MD, PhD
Branch Chief for the Oncology Branch 2 (OB2)
Division of Clinical Evaluation Oncology (DCEO)
Office of Clinical Evaluation (OCE) | CBER
Peter F. Bross, MD
Chief, Oncology Branch
OTP | CBER
Learn more at: www.fda.gov/dr...
-----------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming Training - www.fda.gov/cd...
SBIA Listserv - public.govdeli...
SBIA 2024 Playlist - • 2024 CDER Small Busine...
SBIA LinkedIn -  / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cd...
Twitter -  / fda_drug_info
Email - CDERSBIA@fda.hhs.gov
Phone - (301) 796-6707 I (866) 405-5367

Пікірлер
FDA | NIH: Regulatory Do’s and Don’ts: Tips from FDA - CDRH Segment
55:14
U.S. Food and Drug Administration
Рет қаралды 755
FDA | NIH: Regulatory Do’s and Don'ts: Tips from FDA - CDER Segment
1:16:43
U.S. Food and Drug Administration
Рет қаралды 2,1 М.
Noodles Eating Challenge, So Magical! So Much Fun#Funnyfamily #Partygames #Funny
00:33
Introduction to FDA’s Office of Trade and Global Partnerships
1:00:24
U.S. Food and Drug Administration
Рет қаралды 770
Dataset-JSON Pilot Report and Next Steps
25:39
U.S. Food and Drug Administration
Рет қаралды 946
Clinical Pharmacology Considerations for Radiolabeled Mass Balance Studies
1:00:00
U.S. Food and Drug Administration
Рет қаралды 577
Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020
28:11
Preclinical Considerations for Cell and Gene Therapy Products, an FDA Perspective
46:52
U.S. Food and Drug Administration
Рет қаралды 17 М.
SEND for CBER, What You Need to Know
56:35
U.S. Food and Drug Administration
Рет қаралды 4,8 М.
How is My Medical Device Classified?
16:18
U.S. Food and Drug Administration
Рет қаралды 17 М.
Common CMC (Quality) Issues and How to Avoid Them Part I (12of16) Generic Drugs Forum
57:58
U.S. Food and Drug Administration
Рет қаралды 7 М.
Putting the Pieces Together: REMS Logic Model in REMS Design, Implementation, and Evaluation
1:21:57
77th Cellular, Tissue, and Gene Therapies Advisory Committee
5:59:50
U.S. Food and Drug Administration
Рет қаралды 3,9 М.